KalVista Pharmaceuticals (KALV) Net Cash Flow (QoQ) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 74.30% |
| Oct 31, 2024 | 16,179.31% |
| Jul 31, 2024 | -100.66% |
| Apr 30, 2024 | 125.91% |
| Jan 31, 2024 | -483.67% |
| Oct 31, 2023 | 228.15% |
| Jul 31, 2023 | 76.06% |
| Apr 30, 2023 | -162.77% |
| Jan 31, 2023 | 14,126.52% |
| Oct 31, 2022 | -104.39% |
| Jul 31, 2022 | 152.54% |
| Apr 30, 2022 | -3,536.06% |
| Jan 31, 2022 | 78.74% |
| Oct 31, 2021 | 18.12% |
| Jul 31, 2021 | -106.85% |
| Apr 30, 2021 | 2,986.63% |
| Jan 31, 2021 | 169.82% |
| Oct 31, 2020 | -177.17% |
| Jul 31, 2020 | 176.10% |
| Apr 30, 2020 | 21.37% |
| Jan 31, 2020 | 64.16% |
| Oct 31, 2019 | -554.09% |
| Jul 31, 2019 | 94.24% |
| Apr 30, 2019 | 62.68% |
| Jan 31, 2019 | -188.63% |
| Oct 31, 2018 | 4,133.73% |
| Jul 31, 2018 | 74.06% |
| Apr 30, 2018 | -125.20% |
| Jan 31, 2018 | 482.85% |
| Oct 31, 2017 | -60.38% |
| Jul 31, 2017 | -72.13% |
| Apr 30, 2017 | -111.57% |
| Jan 31, 2017 | 644.53% |
| Oct 31, 2016 | 26.21% |
| Mar 31, 2016 | 14.41% |
| Dec 31, 2015 | -11.85% |
| Sep 30, 2015 | -108.85% |
| Jun 30, 2015 | 8,787.15% |
| Sep 30, 2014 | 202.33% |
| Jun 30, 2014 | -315.84% |